PPARA and diabetes mellitus: Nevertheless, two large-scale clinical trials known as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies have shown that the PPARα-agonist fenofibrate slows the progression of DR [97,98].